Format

Send to

Choose Destination
See comment in PubMed Commons below
Dement Geriatr Cogn Disord. 2004;17(3):117-21. Epub 2004 Jan 20.

Efficacy of fluvoxamine as a treatment for behavioral symptoms in frontotemporal lobar degeneration patients.

Author information

  • 1Department of Neuropsychiatry, Ehime University School of Medicine, Ehime, Japan. mikeda@m.ehime-u.ac.jp

Abstract

Patients with frontotemporal lobar degeneration (FTLD) present a profound personality change, social misconduct, overeating, and stereotyped behavior. We examined the hypothesis that many of the behavioral symptoms of FTLD will respond to selective serotonin reuptake inhibitors (SSRIs). Sixteen FTLD patients were treated with an SSRI (fluvoxamine maleate) in an open 12-week trial. Treatment responses for stereotyped behavior and other neurobehavioral symptoms were evaluated by the Stereotypy Rating Inventory and the Neuropsychiatric Inventory. The behavioral symptoms, especially stereotyped behaviors of FTLD, significantly improved after treatment. Randomized, placebo- and other SSRI-controlled trials may improve available treatments.

Copyright 2004 S. Karger AG, Basel

[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for S. Karger AG, Basel, Switzerland
    Loading ...
    Write to the Help Desk